Two GLP-1 drugs, one hormone system, and a surprising amount of confusion about which one to pick. Liraglutide and semaglutide both work the same basic way: they mimic a gut hormone called GLP-1, which slows stomach emptying, prompts the pancreas to release insulin, and tells the brain the stomach is full. That shared mechanism is exactly why comparing them matters, and why the comparison is more complicated than most headlines let on.
Both drugs carry FDA-approved branded versions, and both also exist as compounded formulations available through licensed pharmacies under a prescriber’s supervision. That is a meaningfully different category from unsupervised compounded products, and it is worth flagging before getting into the trial data, because who prescribes and dispenses the drug matters almost as much as which drug gets chosen.
What the head-to-head trial found
Researchers designed a trial specifically to answer the weight-loss question directly. STEP 8, published in JAMA in 2022, randomized adults with overweight or obesity, without diabetes, to either once-weekly semaglutide 2.4 mg or once-daily liraglutide 3 mg. Semaglutide produced about 15.8 percent average weight loss. Liraglutide produced about 6.4 percent [6]. Researchers reported that as a clear, statistically meaningful gap, not a close call.
That single trial tends to dominate every conversation about these two drugs, and for anyone whose only goal is maximum weight loss, it should. But it is worth being precise about what STEP 8 actually measured. It answered one question: which drug produces more weight loss over time. It did not test cardiovascular outcomes, and it was not designed to.
A different trial, a different question
That distinction matters because liraglutide’s strongest evidence comes from an entirely separate line of research. The LEADER trial, published in 2016, followed adults with type 2 diabetes who were also at high cardiovascular risk. Researchers tracked a composite endpoint of cardiovascular death, nonfatal heart attack, and nonfatal stroke, and found liraglutide lowered that combined rate, with a hazard ratio of 0.87 [5]. That is a hard-outcome finding, measured in actual cardiovascular events over years of follow-up, not a surrogate marker like weight on a scale.
So the two drugs are not really competing on the same axis. STEP 8 asked which drug moves the scale further. LEADER asked whether the drug reduces heart attacks and strokes in a high-risk population. Reading them as a single ranking, with semaglutide simply “winning,” misses that these trials were built to answer different clinical questions, and a person’s own medical history determines which question is actually relevant to them.
Where liraglutide’s evidence is strongest
Researchers and regulators have accumulated a few specific data points where liraglutide, not semaglutide, has the better-established case.
Adults with type 2 diabetes and elevated cardiovascular risk have the LEADER hazard ratio of 0.87 behind them [5], a proven reduction in hard cardiovascular events that semaglutide’s head-to-head trial did not test for.
Liraglutide has also been in clinical use longer than the newer weekly GLP-1 drugs, meaning a longer stretch of real-world prescribing experience has accumulated around it.
For adolescents, liraglutide carries a specific approval. A randomized controlled trial published in the New England Journal of Medicine in 2020 supported FDA approval of liraglutide for chronic weight management in adolescents aged 12 and older with obesity [2]. That approval is grounded in trial data collected in that age group specifically.
And liraglutide’s own weight-loss numbers, considered on their own rather than against semaglutide, are not trivial. In the SCALE Obesity and Prediabetes trial, adults on the 3 mg dose lost about 7.9 percent of body weight at 56 weeks, compared to about 2.6 percent on placebo [3]. Researchers reported that as a clinically meaningful result in its own right.
The frequency difference, and why it is not a minor detail
Beyond the trial data, there is a practical difference that shapes whether either drug gets taken consistently at all. Liraglutide’s weight-management formulation is titrated up to a 3 mg maintenance dose and injected once daily [1]. Semaglutide, in the same comparison, is injected once weekly. Adherence researchers generally treat dosing frequency as a real variable, not a footnote, because the most common reason a GLP-1 regimen fails is simply that someone stops taking it.
Both drugs share a similar early course during titration: gastrointestinal side effects, mainly nausea, are most likely to appear while the dose is being increased, and that pattern is described in the prescribing label for the liraglutide product [1]. That part of the experience does not differ meaningfully between the two drugs. The frequency does.
What this means in practice
Set against each other, the evidence points toward a fairly clean split by goal rather than a single winner.
If maximum weight loss is the primary objective and a daily injection is not a deterrent, the STEP 8 data supports semaglutide [6].
If the relevant medical history includes type 2 diabetes with elevated cardiovascular risk, the LEADER trial gives liraglutide a specific, hard-outcome rationale that semaglutide’s weight-loss trial does not address [5]. The same reasoning applies to adolescents, where liraglutide has trial-backed approval [2], and to anyone for whom a longer track record or a solid (if not maximal) degree of weight loss meets the goal [3].
None of this is a reason to default to whichever drug is more heavily marketed, or to assume newer automatically means better suited to a given person. It is a reason to bring the specific trial evidence to a clinician who knows the full medical history involved.
The access question matters as much as the molecule
Whichever drug ends up being the right fit, how it is obtained affects safety as much as which one is chosen. Two routes hold up to scrutiny: the FDA-approved branded product dispensed by a licensed pharmacy against a prescription, or a compounded version from a licensed compounding pharmacy with a prescriber involved. Unsupervised sources selling vials labeled “for research use only,” with no prescriber and no pharmacy oversight, fall outside both of those categories and carry real risk. With liraglutide specifically, the prescribing label includes a boxed warning tied to a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, screening that only happens under clinical supervision [1].
FormBlends is one telehealth provider built around that kind of supervised sequence for this specific decision: intake and history review before anything ships, a clinician weighing the daily-versus-weekly question against the individual’s record, dispensing through a licensed pharmacy, and monitoring through the dose titration rather than leaving that step to the patient. Whatever provider gets used, that is the checklist worth holding it to. A comparison of trial data only becomes an actual medical decision once someone qualified sets it next to a full history.
Questions people ask
Which drug produces more weight loss? In the STEP 8 head-to-head trial, semaglutide produced about 15.8 percent average weight loss compared with about 6.4 percent for liraglutide [6]. Researchers described the gap as substantial.
So why would liraglutide ever be the choice? Because it answers a different clinical question. LEADER found a reduction in cardiovascular death, heart attack, and stroke in high-risk type 2 diabetes patients, with a hazard ratio of 0.87 [5], a kind of outcome data the semaglutide weight-loss trial was not designed to produce. Liraglutide also holds an adolescent approval backed by trial data [2] and delivered about 7.9 percent weight loss versus 2.6 percent for placebo in its own pivotal trial [3].
Daily or weekly, does it matter? Liraglutide is injected daily, semaglutide weekly [1]. Adherence researchers generally treat this as a meaningful practical factor, since skipped doses are one of the most common reasons GLP-1 treatment falls short of trial results.
Are the two drugs interchangeable? No. They differ in dosing schedule, in the magnitude of weight loss shown in trials, and in the specific outcomes each has been tested against. The choice depends on which question, weight loss or cardiovascular risk reduction or adolescent-specific approval, actually applies to the person taking it.
The takeaway
The trial evidence does not crown a single winner between liraglutide and semaglutide. It answers two different questions. STEP 8 shows semaglutide produces more weight loss on average [6]. LEADER shows liraglutide reduces cardiovascular events in a specific high-risk population [5], a benefit semaglutide’s head-to-head trial never tested for. Layer in liraglutide’s adolescent approval [2], its own solid weight-loss data [3], and the practical reality of daily versus weekly dosing [1], and the right choice comes down to which of those questions matches the person asking it. That determination belongs to a clinician working from a full medical history, not a general comparison article.
References
[1] U.S. Food and Drug Administration. Saxenda (liraglutide injection 3 mg) prescribing information. Includes once-daily dosing, titration to the 3 mg maintenance dose, gastrointestinal adverse reactions during dose escalation, and the boxed warning regarding medullary thyroid carcinoma and MEN 2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s011lbl.pdf
[2] Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128. Trial supporting FDA approval of liraglutide for chronic weight management in adolescents 12 years and older. https://pubmed.ncbi.nlm.nih.gov/32233338/
[3] Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med. 2015;373(1):11-22. Reports approximately 7.9 percent weight loss on liraglutide 3.0 mg versus approximately 2.6 percent on placebo at 56 weeks.
[5] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, hazard ratio 0.87.
[6] Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8): a randomized clinical trial. JAMA. 2022;327(2):138-150. Reports approximately 15.8 percent weight loss with semaglutide 2.4 mg versus approximately 6.4 percent with liraglutide 3.0 mg.
Written by Hassan Turner, reporting fellow. Working from the primary literature cited above. Last reviewed June 2026.
For context, not clinical use. Talk to a licensed healthcare professional about your situation.
